Aspirin
Bamlanivimab
Bromhexine
Budesonide
Casirivimab/i..
Colchicine
Conv. Plasma
Curcumin
Favipiravir
Fluvoxamine
Hydroxychloro..
Iota-carragee..
Ivermectin
Melatonin
Molnupiravir
Nigella Sativa
Nitazoxanide
Povidone-Iod..
Probiotics
Proxalutamide
Quercetin
Remdesivir
Sotrovimab
Vitamin A
Vitamin C
Vitamin D
Zinc

Other
Feedback
Home
Top
All studies
Exclusions
Mortality
ICU
Serious outcomes
Cases
Viral clearance
RCTs
RCT mortality
Peer-reviewed
All outcomes

Feedback
Home   COVID-19 treatment studies for Aspirin  COVID-19 treatment studies for Aspirin  C19 studies: Aspirin  Aspirin   Select treatmentSelect treatmentTreatmentsTreatments
Aspirin Molnupiravir
Bamlanivimab Nigella Sativa
Bromhexine Nitazoxanide
Budesonide Povidone-Iod..
Casirivimab/i.. Probiotics
Colchicine Proxalutamide
Conv. Plasma Quercetin
Curcumin Remdesivir
Favipiravir Sotrovimab
Fluvoxamine Vitamin A
Hydroxychloro.. Vitamin C
Iota-carragee.. Vitamin D
Ivermectin Zinc
Melatonin

Other Adoption
Outcomes in COVID-19 aspirin studies
00.250.50.7511.251.51.752+Meizlish (PSM)48%0.52 [0.34-0.81]death319 (n)319 (n)Improvement, RR [CI]TreatmentControlLiu (PSM)75%0.25 [0.07-0.87]death2/2811/204Mura20%0.80 [0.66-0.96]death527 (n)527 (n)Chow47%0.53 [0.31-0.90]death26/9873/314Sahai (PSM)13%0.87 [0.56-1.34]death33/24838/248Horby (RCT)4%0.96 [0.89-1.04]death1,222/7,3511,299/7,541Abdelwahab-8%1.08 [0.15-3.82]ventilation11/316/36Al Harthi (PSM)27%0.73 [0.56-0.97]death98/176107/173Kim (PSM)34%0.66 [0.36-1.23]death14/12423/135Tau​2 = 0.03; I​2 = 71.4%Late treatment25%0.75 [0.63-0.89]1,406/8,9021,557/9,49725% improvementYuan4%0.96 [0.47-1.72]death11/5229/131Improvement, RR [CI]TreatmentControlOsborne (PSM)59%0.41 [0.35-0.48]death272/6,300661/6,300Mulhem-14%1.14 [0.93-1.40]death300/1,354216/1,865Chow (PSM)19%0.81 [0.76-0.87]death1,280/6,7812,271/10,566Kim (PSM)-700%8.00 [1.07-59.6]death6/151/20Tau​2 = 0.19; I​2 = 96.5%PrEP17%0.83 [0.54-1.30]1,869/14,5023,178/18,88217% improvementAll studies25%0.75 [0.62-0.90]3,275/23,4044,735/28,37925% improvement14 aspirin COVID-19 studiesc19aspirin.com Sep 24, 2021Tau​2 = 0.08; I​2 = 91.6%; Z = 3.14Effect extraction pre-specifiedFavors aspirinFavors control 00.250.50.7511.251.51.752+Meizlish (PSM)48%0.52 [0.34-0.81]death319 (n)319 (n)Improvement, RR [CI]TreatmentControlLiu (PSM)75%0.25 [0.07-0.87]death2/2811/204Mura20%0.80 [0.66-0.96]death527 (n)527 (n)Chow47%0.53 [0.31-0.90]death26/9873/314Sahai (PSM)13%0.87 [0.56-1.34]death33/24838/248Horby (RCT)4%0.96 [0.89-1.04]death1,222/7,3511,299/7,541Abdelwahab-8%1.08 [0.15-3.82]ventilation11/316/36Al Harthi (PSM)27%0.73 [0.56-0.97]death98/176107/173Kim (PSM)34%0.66 [0.36-1.23]death14/12423/135Tau​2 = 0.03; I​2 = 71.4%Late treatment25%0.75 [0.63-0.89]1,406/8,9021,557/9,49725% improvementYuan4%0.96 [0.47-1.72]death11/5229/131Improvement, RR [CI]TreatmentControlOsborne (PSM)59%0.41 [0.35-0.48]death272/6,300661/6,300Chow (PSM)19%0.81 [0.76-0.87]death1,280/6,7812,271/10,566Kim (PSM)-700%8.00 [1.07-59.6]death6/151/20Tau​2 = 0.23; I​2 = 96.6%PrEP23%0.77 [0.44-1.35]1,569/13,1482,962/17,01723% improvementAll studies29%0.71 [0.59-0.86]2,975/22,0504,519/26,51429% improvement13 aspirin COVID-19 studies after exclusionsc19aspirin.com Sep 24, 2021Tau​2 = 0.07; I​2 = 91.2%; Z = 3.51Effect extraction pre-specifiedFavors aspirinFavors control 00.250.50.7511.251.51.752+Meizlish (PSM)48%0.52 [0.34-0.81]319 (n)319 (n)Improvement, RR [CI]TreatmentControlLiu (PSM)75%0.25 [0.07-0.87]2/2811/204Mura20%0.80 [0.66-0.96]527 (n)527 (n)Chow47%0.53 [0.31-0.90]26/9873/314Sahai (PSM)13%0.87 [0.56-1.34]33/24838/248Horby (RCT)4%0.96 [0.89-1.04]1,222/7,3511,299/7,541Al Harthi (PSM)27%0.73 [0.56-0.97]98/176107/173Kim (PSM)34%0.66 [0.36-1.23]14/12423/135Tau​2 = 0.03; I​2 = 74.8%Late treatment26%0.74 [0.62-0.88]1,395/8,8711,551/9,46126% improvementYuan4%0.96 [0.47-1.72]11/5229/131Improvement, RR [CI]TreatmentControlOsborne (PSM)59%0.41 [0.35-0.48]272/6,300661/6,300Mulhem-14%1.14 [0.93-1.40]300/1,354216/1,865Chow (PSM)19%0.81 [0.76-0.87]1,280/6,7812,271/10,566Kim (PSM)-700%8.00 [1.07-59.6]6/151/20Tau​2 = 0.19; I​2 = 96.5%PrEP17%0.83 [0.54-1.30]1,869/14,5023,178/18,88217% improvementAll studies26%0.74 [0.62-0.89]3,264/23,3734,729/28,34326% improvement13 aspirin COVID-19 mortality resultsc19aspirin.com Sep 24, 2021Tau​2 = 0.08; I​2 = 92.3%; Z = 3.21Favors aspirinFavors control 00.250.50.7511.251.51.752+Chow43%0.57 [0.38-0.85]38/98160/314Improvement, RR [CI]TreatmentControlKim (PSM)-91%1.91 [0.57-6.35]7/1244/135Tau​2 = 0.53; I​2 = 72.8%Late treatment10%0.90 [0.29-2.83]45/222164/44910% improvementKim (PSM)-433%5.33 [0.66-43.0]4/151/20Improvement, RR [CI]TreatmentControlTau​2 = 0.00; I​2 = 0.0%PrEP-433%5.33 [0.66-43.0]4/151/20-433% improvementAll studies-34%1.34 [0.38-4.72]49/237165/469-34% improvement3 aspirin COVID-19 ICU resultsc19aspirin.com Sep 24, 2021Tau​2 = 0.86; I​2 = 74.3%; Z = 0.46Favors aspirinFavors control 00.250.50.7511.251.51.752+Meizlish (PSM)48%0.52 [0.34-0.81]death319 (n)319 (n)Improvement, RR [CI]TreatmentControlLiu (PSM)75%0.25 [0.07-0.87]death2/2811/204Mura20%0.80 [0.66-0.96]death527 (n)527 (n)Chow47%0.53 [0.31-0.90]death26/9873/314Sahai (PSM)13%0.87 [0.56-1.34]death33/24838/248Horby (RCT)4%0.96 [0.89-1.04]death1,222/7,3511,299/7,541Abdelwahab-8%1.08 [0.15-3.82]ventilation11/316/36Al Harthi (PSM)27%0.73 [0.56-0.97]death98/176107/173Kim (PSM)34%0.66 [0.36-1.23]death14/12423/135Tau​2 = 0.03; I​2 = 71.4%Late treatment25%0.75 [0.63-0.89]1,406/8,9021,557/9,49725% improvementYuan4%0.96 [0.47-1.72]death11/5229/131Improvement, RR [CI]TreatmentControlOsborne (PSM)59%0.41 [0.35-0.48]death272/6,300661/6,300Mulhem-14%1.14 [0.93-1.40]death300/1,354216/1,865Chow (PSM)19%0.81 [0.76-0.87]death1,280/6,7812,271/10,566Kim (PSM)-700%8.00 [1.07-59.6]death6/151/20Tau​2 = 0.19; I​2 = 96.5%PrEP17%0.83 [0.54-1.30]1,869/14,5023,178/18,88217% improvementAll studies25%0.75 [0.62-0.90]3,275/23,4044,735/28,37925% improvement14 aspirin COVID-19 serious outcomesc19aspirin.com Sep 24, 2021Tau​2 = 0.08; I​2 = 91.6%; Z = 3.14Effect extraction pre-specifiedFavors aspirinFavors control 00.250.50.7511.251.51.752+Kim (PSM)33%0.67 [0.30-1.36]15/13620/136Improvement, RR [CI]TreatmentControlTau​2 = 0.00; I​2 = 0.0%PrEP33%0.67 [0.30-1.36]15/13620/13633% improvementAll studies33%0.67 [0.36-1.25]15/13620/13633% improvement1 aspirin COVID-19 case resultc19aspirin.com Sep 24, 2021Tau​2 = 0.00; I​2 = 0.0%; Z = 1.27Favors aspirinFavors control 00.250.50.7511.251.51.752+Liu (PSM)-2%1.02 [0.64-1.61]viral time24 (n)24 (n)Improvement, RR [CI]TreatmentControlTau​2 = 0.00; I​2 = 0.0%Late treatment-2%1.02 [0.64-1.61]0/240/24-2% improvementAll studies-2%1.02 [0.64-1.61]0/240/24-2% improvement1 aspirin COVID-19 viral clearance resultc19aspirin.com Sep 24, 2021Tau​2 = 0.00; I​2 = 0.0%; Z = 0.08Favors aspirinFavors control 00.250.50.7511.251.51.752+Horby (RCT)4%0.96 [0.89-1.04]death1,222/7,3511,299/7,541Improvement, RR [CI]TreatmentControlTau​2 = 0.00; I​2 = 0.0%Late treatment4%0.96 [0.89-1.04]1,222/7,3511,299/7,5414% improvementAll studies4%0.96 [0.89-1.03]1,222/7,3511,299/7,5414% improvement1 aspirin COVID-19 Randomized Controlled Trialsc19aspirin.com Sep 24, 2021Tau​2 = 0.00; I​2 = 0.0%; Z = 1.12Effect extraction pre-specifiedFavors aspirinFavors control 00.250.50.7511.251.51.752+Horby (RCT)4%0.96 [0.89-1.04]1,222/7,3511,299/7,541Improvement, RR [CI]TreatmentControlTau​2 = 0.00; I​2 = 0.0%Late treatment4%0.96 [0.89-1.04]1,222/7,3511,299/7,5414% improvementAll studies4%0.96 [0.89-1.03]1,222/7,3511,299/7,5414% improvement1 aspirin COVID-19 RCT mortality resultc19aspirin.com Sep 24, 2021Tau​2 = 0.00; I​2 = 0.0%; Z = 1.12Favors aspirinFavors control 00.250.50.7511.251.51.752+Meizlish (PSM)48%0.52 [0.34-0.81]death319 (n)319 (n)Improvement, RR [CI]TreatmentControlLiu (PSM)75%0.25 [0.07-0.87]death2/2811/204Chow47%0.53 [0.31-0.90]death26/9873/314Sahai (PSM)13%0.87 [0.56-1.34]death33/24838/248Abdelwahab-8%1.08 [0.15-3.82]ventilation11/316/36Kim (PSM)34%0.66 [0.36-1.23]death14/12423/135Tau​2 = 0.03; I​2 = 24.5%Late treatment37%0.63 [0.49-0.82]86/848151/1,25637% improvementYuan4%0.96 [0.47-1.72]death11/5229/131Improvement, RR [CI]TreatmentControlOsborne (PSM)59%0.41 [0.35-0.48]death272/6,300661/6,300Mulhem-14%1.14 [0.93-1.40]death300/1,354216/1,865Chow (PSM)19%0.81 [0.76-0.87]death1,280/6,7812,271/10,566Kim (PSM)-700%8.00 [1.07-59.6]death6/151/20Tau​2 = 0.19; I​2 = 96.5%PrEP17%0.83 [0.54-1.30]1,869/14,5023,178/18,88217% improvementAll studies28%0.72 [0.54-0.97]1,955/15,3503,329/20,13828% improvement11 aspirin COVID-19 peer reviewed trialsc19aspirin.com Sep 24, 2021Tau​2 = 0.16; I​2 = 92.0%; Z = 2.18Effect extraction pre-specifiedFavors aspirinFavors control 00.250.50.7511.251.51.752+Meizlish (PSM)48%0.52 [0.34-0.81]death319 (n)319 (n)Improvement, RR [CI]TreatmentControlLiu (PSM)75%0.25 [0.07-0.87]death2/2811/204Liu (PSM)81%0.19 [0.05-0.78]death1/289/204Liu (PSM)-2%1.02 [0.64-1.61]viral time24 (n)24 (n)Mura20%0.80 [0.66-0.96]death527 (n)527 (n)Mura37%0.63 [0.47-0.83]death305 (n)305 (n)Chow47%0.53 [0.31-0.90]death26/9873/314Chow44%0.56 [0.37-0.85]ventilation35/98152/314Chow43%0.57 [0.38-0.85]ICU38/98160/314Sahai (PSM)13%0.87 [0.56-1.34]death33/24838/248Horby (RCT)4%0.96 [0.89-1.04]death1,222/7,3511,299/7,541Horby (RCT)17%0.83 [0.66-1.04]death129/466169/513Horby (RCT)7%0.93 [0.82-1.05]death1,222/7,3511,299/7,541Horby (RCT)5%0.95 [0.87-1.05]ventilation772/6,993829/7,169Abdelwahab-8%1.08 [0.15-3.82]ventilation11/316/36Al Harthi (PSM)27%0.73 [0.56-0.97]death98/176107/173Al Harthi (PSM)14%0.86 [0.65-1.14]death95/17697/175Kim (PSM)34%0.66 [0.36-1.23]death14/12423/135Kim (PSM)-102%2.02 [0.83-4.90]ventilation13/1247/135Kim (PSM)-91%1.91 [0.57-6.35]ICU7/1244/135Yuan4%0.96 [0.47-1.72]death11/5229/131Osborne (PSM)59%0.41 [0.35-0.48]death272/6,300661/6,300Osborne (PSM)60%0.40 [0.33-0.48]death170/6,814427/6,814Mulhem-14%1.14 [0.93-1.40]death300/1,354216/1,865Chow (PSM)19%0.81 [0.76-0.87]death1,280/6,7812,271/10,566Chow (PSM)3%0.97 [0.93-1.02]ventilation2,122/6,7813,403/10,566Kim (PSM)-700%8.00 [1.07-59.6]death6/151/20Kim (PSM)-433%5.33 [0.66-43.0]ventilation4/151/20Kim (PSM)-433%5.33 [0.66-43.0]ICU4/151/20Kim (PSM)33%0.67 [0.30-1.36]cases15/13620/136Kim (PSM)34%0.66 [0.36-1.23]death14/12423/135Kim (PSM)-102%2.02 [0.83-4.90]ventilation13/1247/135Kim (PSM)-91%1.91 [0.57-6.35]ICU7/1244/135aspirin COVID-19 outcomesc19aspirin.com Sep 24, 2021Favors aspirinFavors control
Please send us corrections, updates, or comments. Vaccines and treatments are both extremely valuable and complementary. All practical, effective, and safe means should be used. Elimination of COVID-19 is a race against viral evolution. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. Denying the efficacy of any method increases the risk of COVID-19 becoming endemic; and increases mortality, morbidity, and collateral damage. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. Treatment protocols for physicians are available from the FLCCC.
  or use drag and drop   
Thanks for your feedback! Please search before submitting papers and note that studies are listed under the date they were first available, which may be the date of an earlier preprint.
Submit